Summary for Investors

Renovos is an exciting, low risk opportunity for bioscience investors.

Broad platform technology: nanoclay has a wide range of applications, making step change improvements in a wide range of current procedures.  Renovos’ success is not dependent on a single product.

Growing market: In the first instance, Renovos is focussed on orthopaedic regenerative medicine. This sector is highly profitable and growing fast, driven by an ageing population and the economic cost of bone fractures that need re-work.

Low technical risk: all of Renovos’ work is underpinned by years of research by the same core team. This has built up the skills and know-how of the team, facilitating technical success and rapid  product development.

Low development risk: all of Renovos’ work is based on nanoclay and well established therapeutic agents. Nanoclay is already used as a component in some drugs and cosmetics and carries low developmental risk.

Easy scale-up: Renovos’ core skills and IP lie in formulation and development, and all the processes developed to date can be expanded and scaled without major technical challenges.

Addressing existing markets: Renovos is developing step change improvements of products with existing market positions. Routes to market are already established and the sales process will be straightforward, and focussed on selling improved products, that are easier to use and more effective, and most importantly safer.

Range of exit routes for investors: Renovos is planning to generate cash from a range of licenses to orthopaedic majors, by product and by territory. These will allow Renovos to continue to fund further developments without the costs of developing an independent route to market. At some point a major company, seeking a profitable platform technology that provides competitive advantage is expected to make an approach for a trade sale.

About Renovos proprietary Nanoclay technologies: